![Stephen L. Bandak](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stephen L. Bandak
Director/Board Member at
Hapten Sciences, Inc.
Profile
Stephen L.
Bandak is currently the Director at Hapten Sciences, Inc. and a Member of The Royal College of Physicians since 1977.
He was previously the Vice President-Medical & Regulatory Affairs at Novavax, Inc. and the Chief Medical Officer at Synosia Therapeutics AG from 2007 to 2011, at Biotie Therapies Oy from 2011 to 2016, and at Synosia Therapeutics, Inc. from 2007 to 2011.
Stephen L. Bandak active positions
| Companies | Position | Start |
|---|---|---|
Hapten Sciences, Inc.
 Hapten Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which manufactures molecule products | Director/Board Member | - |
The Royal College of Physicians
 The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1977 |
Former positions of Stephen L. Bandak
| Companies | Position | End |
|---|---|---|
| BIOTIE THERAPIES CORP | Chief Tech/Sci/R&D Officer | 30/06/2016 |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of psychiatry and neurology diseases | Chief Tech/Sci/R&D Officer | 01/01/2011 |
Synosia Therapeutics, Inc.
 Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops products for unmet medical needs in psychiatry and neurology | Chief Tech/Sci/R&D Officer | 01/01/2011 |
| NOVAVAX, INC. | Chief Tech/Sci/R&D Officer | 19/09/2011 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
77
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Novavax, Inc.
 Novavax, Inc. BiotechnologyHealth Technology Engages in development of novel recombinant vaccines | Health Technology |
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of psychiatry and neurology diseases | Health Technology |
Hapten Sciences, Inc.
Hapten Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which manufactures molecule products | Health Technology |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
The Royal College of Physicians
The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Synosia Therapeutics, Inc.
Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops products for unmet medical needs in psychiatry and neurology | Health Technology |
- Stock Market
- Insiders
- Stephen L. Bandak
